His Multiple myeloma study frequently draws connections to adjacent fields such as Daratumumab. His research combines Bortezomib and Daratumumab. He undertakes interdisciplinary study in the fields of Bortezomib and Multiple myeloma through his research. Maria-Victoria Mateos connects Oncology with Intensive care medicine in his study. Maria-Victoria Mateos performs integrative study on Intensive care medicine and Oncology. Borrowing concepts from Proteasome inhibitor, he weaves in ideas under Carfilzomib. He performs multidisciplinary study on Proteasome inhibitor and Carfilzomib in his works. His studies link Disease with Internal medicine. His research on Disease often connects related topics like Internal medicine.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.
S. Vincent Rajkumar;Meletios A. Dimopoulos;Antonio Palumbo;Joan Blade.
Lancet Oncology (2014)
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
Jesús F. San Miguel;Rudolf Schlag;Nuriet K. Khuageva;Meletios A. Dimopoulos.
The New England Journal of Medicine (2008)
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
Shaji Kumar;Bruno Paiva;Kenneth C. Anderson;Brian Durie.
Lancet Oncology (2016)
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
Antonio Palumbo;Asher Chanan-Khan;Katja Christina Weisel;Ajay K Nooka.
The New England Journal of Medicine (2016)
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
Abstr Act;Sagar Lonial;Meletios Dimopoulos;Antonio Palumbo.
The New England Journal of Medicine (2015)
International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders
A. Dispenzieri;R. Kyle;G. Merlini;J. S. Miguel.
Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial
Sagar Lonial;Brendan M Weiss;Saad Z Usmani;Seema Singhal.
The Lancet (2016)
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma.
María-Victoria Mateos;Meletios A. Dimopoulos;Michele Cavo;Kenshi Suzuki.
The New England Journal of Medicine (2017)
Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group
Pieter Sonneveld;Hervé Avet-Loiseau;Sagar Lonial;Saad Usmani.
Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
P. Moreau;J. San Miguel;P. Sonneveld;M. V. Mateos.
Annals of Oncology (2010)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: